272 related articles for article (PubMed ID: 27879972)
1. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).
Ishii M; Hirai I; Tanese K; Fusumae T; Nakamura Y; Fukuda K; Uchi H; Kabashima K; Otsuka A; Yokota K; Yamazaki N; Namikawa K; Fujimura T; Takenouchi T; Yamamoto Y; Nishiguchi M; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2020 Oct; 99(44):e22913. PubMed ID: 33126349
[TBL] [Abstract][Full Text] [Related]
3. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
4. Non-Melanoma Skin Cancers: Biological and Clinical Features.
Cives M; Mannavola F; Lospalluti L; Sergi MC; Cazzato G; Filoni E; Cavallo F; Giudice G; Stucci LS; Porta C; Tucci M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751327
[TBL] [Abstract][Full Text] [Related]
5. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.
Nagasaka M; Zaki M; Kim H; Raza SN; Yoo G; Lin HS; Sukari A
J Immunother Cancer; 2016; 4():83. PubMed ID: 27895920
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Clingan P; Ladwa R; Brungs D; Harris DL; McGrath M; Arnold S; Coward J; Fourie S; Kurochkin A; Malan DR; Mant A; Sharma V; Shue H; Tazbirkova A; Berciano-Guerrero MA; Charoentum C; Dalle S; Dechaphunkul A; Dudnichenko O; Koralewski P; Lugowska I; Montaudié H; Muñoz-Couselo E; Sriuranpong V; Oliviero J; Desai J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37848259
[TBL] [Abstract][Full Text] [Related]
8. Rapid Life-Saving Response to Anti-PD-1 in a Solid Organ Transplant Recipient With Metastatic Cutaneous Squamous Cell Carcinoma: A Case Report and Review.
Antonelli JP; Quach M; Mahajan A; Pleva J; Ma VT
J Immunother; 2024 Jul-Aug 01; 47(6):216-219. PubMed ID: 38532708
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract][Full Text] [Related]
10. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers.
Ravipati A; Pradeep T; Nouri K
J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
[TBL] [Abstract][Full Text] [Related]
11. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma.
Corbett M; Tohani S; Ramli R; O'Duffy F
JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669
[TBL] [Abstract][Full Text] [Related]
12. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
13. High-throughput lipidomic profiles sampled with electroporation-based biopsy differentiate healthy skin, cutaneous squamous cell carcinoma, and basal cell carcinoma.
Louie L; Wise J; Berl A; Shir-Az O; Kravtsov V; Yakhini Z; Shalom A; Golberg A; Vitkin E
Skin Res Technol; 2024 May; 30(5):e13706. PubMed ID: 38721854
[TBL] [Abstract][Full Text] [Related]
14. Expression of Early Growth Response 3 in Skin Cancers.
Zhou KY; Deng LJ; Luo SY; Wang QX; Fang S
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):169-175. PubMed ID: 38478384
[TBL] [Abstract][Full Text] [Related]
15. METTL3-mediated HPV vaccine enhances the effect of anti PD-1 immunotherapy to alleviate the development of cutaneous squamous cell carcinoma.
Zhang Y; Wang Y; Guo S; Cui H
An Bras Dermatol; 2024; 99(2):210-222. PubMed ID: 38030537
[TBL] [Abstract][Full Text] [Related]
16. Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
Stonesifer CJ; Djavid AR; Grimes JM; Khaleel AE; Soliman YS; Maisel-Campbell A; Garcia-Saleem TJ; Geskin LJ; Carvajal RD
Front Oncol; 2021; 11():734354. PubMed ID: 34988009
[TBL] [Abstract][Full Text] [Related]
18. Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy.
Furkert C; Martin R; Sharma A; Rivalland G
World J Surg Oncol; 2023 Sep; 21(1):291. PubMed ID: 37715254
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab.
Hober C; Jamme P; Desmedt E; Greliak A; Mortier L
Ther Adv Med Oncol; 2021; 13():17588359211015493. PubMed ID: 34104225
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment of Metastatic Primary Cutaneous Adnexal Carcinoma With a PD-1 Inhibitor.
Patel JD; Pozorski VJ; Tavberidze N; Buehler DG; Huang W; Bennett DD; Ma VT
J Immunother; 2024 Apr; ():. PubMed ID: 38664936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
